Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) went up by 0.19% from its latest closing price compared to the recent 1-year high of $242.99. The company’s stock price has collected 2.22% of gains in the last five trading sessions. Press Release reported on 01/11/22 that European Commission Approves KAFTRIO(R) (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
Is It Worth Investing in Vertex Pharmaceuticals Incorporated (NASDAQ :VRTX) Right Now?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) scored a price-to-earnings ratio above its average ratio, recording 27.16 x from its present earnings ratio. Plus, the 36-month beta value for VRTX is at 0.63. Opinions of the stock are interesting as 16 analysts out of 27 who provided ratings for Vertex Pharmaceuticals Incorporated declared the stock was a “buy,” while 3 rated the stock as “overweight,” 7 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $263.18, which is $30.95 above the current price. VRTX currently public float of 253.83M and currently shorts hold a 1.15% ratio of that float. Today, the average trading volume of VRTX was 1.86M shares.
VRTX’s Market Performance
VRTX stocks went up by 2.22% for the week, with a monthly jump of 8.29% and a quarterly performance of 24.56%, while its annual performance rate touched 0.20%. The volatility ratio for the week stands at 1.99% while the volatility levels for the past 30 days are set at 1.89% for Vertex Pharmaceuticals Incorporated. The simple moving average for the period of the last 20 days is 2.67% for VRTX stocks with a simple moving average of 12.95% for the last 200 days.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with Wells Fargo repeating the rating for VRTX by listing it as a “Overweight.” The predicted price for VRTX in the upcoming period, according to Wells Fargo is $270 based on the research report published on December 09th of the previous year 2021.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $202. The rating they have provided for VRTX stocks is “Market Perform” according to the report published on November 19th, 2021.
Piper Sandler gave a rating of “Neutral” to VRTX, setting the target price at $218 in the report published on November 19th of the previous year.
VRTX Trading at 10.78% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.75% of loss for the given period.
Volatility was left at 1.89%, however, over the last 30 days, the volatility rate increased by 1.99%, as shares surge +7.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.91% upper at present.
During the last 5 trading sessions, VRTX rose by +2.22%, which changed the moving average for the period of 200-days by +5.44% in comparison to the 20-day moving average, which settled at $221.46. In addition, Vertex Pharmaceuticals Incorporated saw 3.18% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at VRTX starting from Sachdev Amit, who sale 51 shares at the price of $187.19 back on Nov 15. After this action, Sachdev Amit now owns 31,928 shares of Vertex Pharmaceuticals Incorporated, valued at $9,547 using the latest closing price.
Arbuckle Stuart A, the EVP, COO of Vertex Pharmaceuticals Incorporated, sale 3 shares at $187.26 during a trade that took place back on Nov 15, which means that Arbuckle Stuart A is holding 41,103 shares at $562 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- +46.27 for the present operating margin
- +88.14 for the gross margin
The net margin for Vertex Pharmaceuticals Incorporated stands at +43.67. The total capital return value is set at 35.06, while invested capital returns managed to touch 33.30. Equity return is now at value 23.90, with 17.90 for asset returns.
Based on Vertex Pharmaceuticals Incorporated (VRTX), the company’s capital structure generated 10.85 points at debt to equity in total, while total debt to capital is 9.79. Total debt to assets is 8.02, with long-term debt to equity ratio resting at 10.24. Finally, the long-term debt to capital ratio is 9.24.
When we switch over and look at the enterprise to sales, we see a ratio of 7.21, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 8.18 and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.33.